DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Pegaspargase

Pegaspargase

  • BC Cancer Benefit Drug List September 2021

    BC Cancer Benefit Drug List September 2021

  • Australian Public Assessment Report for Pegaspargase

    Australian Public Assessment Report for Pegaspargase

  • Acute Lymphoblastic Leukaemia: ALL06 Schema

    Acute Lymphoblastic Leukaemia: ALL06 Schema

  • Oncaspar, INN-Pegaspargase

    Oncaspar, INN-Pegaspargase

  • Prescribing Information | VELCADE® (Bortezomib)

    Prescribing Information | VELCADE® (Bortezomib)

  • Acute Lymphoblastic Leukemia (ALL) (Part 1 Of

    Acute Lymphoblastic Leukemia (ALL) (Part 1 Of

  • Negative Change Add Inclusion Criteria

    Negative Change Add Inclusion Criteria

  • Standard Oncology Criteria C16154-A

    Standard Oncology Criteria C16154-A

  • Cancer Drug Costs for a Month of Treatment at Initial Food and Drug

    Cancer Drug Costs for a Month of Treatment at Initial Food and Drug

  • Velcade® (Bortezomib)

    Velcade® (Bortezomib)

  • Overview of the Current Treatment Strategy in Extranodal NK/T-Cell Lymphoma: from Diagnosis to Recurrence

    Overview of the Current Treatment Strategy in Extranodal NK/T-Cell Lymphoma: from Diagnosis to Recurrence

  • Evaluation of Immunologic Crossreaction of Antiasparaginase Antibodies in Acute Lymphoblastic Leukemia (ALL) and Lymphoma Patien

    Evaluation of Immunologic Crossreaction of Antiasparaginase Antibodies in Acute Lymphoblastic Leukemia (ALL) and Lymphoma Patien

  • Haematologica August 2021

    Haematologica August 2021

  • Cancer Drug Costs for a Month of Treatment at Initial Food

    Cancer Drug Costs for a Month of Treatment at Initial Food

  • Proposal for the Inclusion of PEG-E Coli Asparaginase in the WHO Model List of ESSENTIAL MEDICINES for the Treatment of Acute Lymphoblastic Leukemia

    Proposal for the Inclusion of PEG-E Coli Asparaginase in the WHO Model List of ESSENTIAL MEDICINES for the Treatment of Acute Lymphoblastic Leukemia

  • NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010

    NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010

  • Asparaginase

    Asparaginase

  • Oncaspar (Pegaspargase) Injection, for Intramuscular Or Intravenous ® Use • History of Serious Allergic Reactions to Oncaspar (4) Initial U.S

    Oncaspar (Pegaspargase) Injection, for Intramuscular Or Intravenous ® Use • History of Serious Allergic Reactions to Oncaspar (4) Initial U.S

Top View
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
  • Pegaspargase (Oncaspar)
  • Pegaspargase (Oncaspar) for Acute Lymphoblastic Leukaemia
  • How to Order Chemotherapy at Shands at the University of Florida - Inpatient
  • List Item Oncaspar : EPAR
  • Chemical Compatibility of Chemoclave™ and Chemolock™
  • NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
  • Hemodialysis Drug Removal
  • Adult Antiemetic Management of Chemotherapy-Induced Nausea
  • Oncology Agents Not Listed in Seer Book 8
  • Appendix B. Drug Codes Requiring Authorization the Following Codes Will Require Authorization for MA Effective Oct 1, 2017 Page
  • A New Asparaginase for Acute Lymphoblastic Leukemia
  • 34293 COVID Vaccine Clinicia
  • LYASPMEDEX Protocol
  • Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
  • Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
  • AHFS Pharmacologic-Therapeutic Classification System
  • 2020 Table of Drugs


© 2024 Docslib.org    Feedback